Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

Background: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease...

ver descrição completa

Detalhes bibliográficos
Principais autores: Abdessamad El Kaoutari, Nicolas A. Fraunhoffer, Owen Hoare, Carlos Teyssedou, Philippe Soubeyran, Odile Gayet, Julie Roques, Gwen Lomberk, Raul Urrutia, Nelson Dusetti, Juan Iovanna
Formato: Artigo
Idioma:English
Publicado em: Elsevier 2021-04-01
coleção:EBioMedicine
Assuntos:
Pancreatic cancer
Metabolomics
Chemosensitivity
Tumor heterogeneity
Metabolic signature
Precision medicine
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2352396421001250

Internet

http://www.sciencedirect.com/science/article/pii/S2352396421001250

Registros relacionados